Teva announces recruitment completion of Phase III clinical Study of mdc-TJK/Olanzapine LAI

Published: 10-Jan-2024

Teva Pharmaceutical Industries announced the successful completion of the enrollment in the EU and US of the anticipated 640 participants of the ongoing Phase III clinical trial of mdc-TJK (TEV-44749) at the J.P. Morgan Healthcare Conference

Results of the study are expected in the second half of 2024. mdc-TJK is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the
treatment of schizophrenia.

It has the potential to be the first long-acting olanzapine with a favorable safety profile. Teva remains fully responsible to lead the development and commercialisation of olanzapine LAI globally.

MedinCell may receive up to $117m in development and commercial milestones during the coming years for mdc-TJK, and is eligible for royalties on all net sales.

You may also like